TrialAmerican journal of hematology2023

Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.

Tapan M Kadia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.